Skip to main content
SpringerLink
Log in
Book cover

LH-RH Agonists in Oncology

  • Conference proceedings
  • © 1988

Overview

Editors:
  1. Klaus Höffken

    1. Innere Klinik und Poliklinik Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Essen 1, Federal Republic of Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (17 papers)

  1. Front Matter

    Pages I-XIX
    Download chapter PDF

  2. Mechanisms of Action

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. Gonadotropin-Releasing Hormone: Physiological and Endocrinological Aspects

      • D. Klingmüller, H. U. Schweikert
      Pages 3-9

    3. Preclinical Studies on Suppression of Follicular Maturation and Oestrogen Secretion in Rats and Monkeys

      • J. Sandow, H. M. Fraser, K. Engelbart, H. Seidel, H. Donaubauer, W. von Rechenberg
      Pages 10-21

    4. Direct Antitumor Effects of an LH-RH Agonist

      • J. A. Foekens, J. G. M. Klijn
      Pages 22-29

  3. Prostatic Cancer

    1. Front Matter

      Pages 31-31
      Download chapter PDF

    2. Comments on the Management of Metastatic Prostatic Cancer With LH-RH Analogues

      • F. H. Schröder
      Pages 33-40

    3. Results of the Treatment of Locally Advanced Prostatic Carcinoma with LH-RH Analogues

      • R. Nagel, H. Al-Abadi, V. Borgmann
      Pages 41-59

    4. Combination Therapy with Flutamide and Castration (Orchiectomy or LH-RH Agonist) in Untreated Patients with Advanced Prostate Cancer

      • A. Dupont, F. Labrie, M. Giguère, J. P. Borsanyi, Y. Lacourciere, A. Bélanger et al.
      Pages 60-71

    5. LH-RH Analogues for Palliation of Advanced Prostatic Carcinoma. A Critical Review After Five Years of Experience

      • G. H. Jacobi, U. K. Wenderoth, H. v. Wallenberg, M. Gatto, R. Hohenfellner
      Pages 72-88

  5. Breast Cancer

    1. Front Matter

      Pages 129-129
      Download chapter PDF

    2. Clinical Trials of the LH-RH Analogue Leuprolide in Human Breast Cancer

      • H. A. Harvey, A. Lipton, D. T. Max
      Pages 131-138

    3. LH-RH Agonists in the Treatment of Metastatic Breast Cancer: Five Years Experience

      • J. G. M. Klijn
      Pages 139-148

    4. Buserelin in the Treatment of Premenopausal Patients with Advanced Breast Cancer

      • K. Höffken, R. Becher, E. Kurschel, C. Doberauer, C. U. Anders, R. Callies et al.
      Pages 149-163

    5. Treatment of Postmenopausal Women with Breast Cancer with Gonadotropin-Releasing Hormone Analogues

      • J. Waxman
      Pages 164-167
Back to top

Keywords

About this book

Hormonal treatment of malignant diseases came of age quite some years ago. Nevertheless, developments in this field are still progressing at a steady pace. During recent years, the detection of new endocrine feedback loops and the availability of new classes of hormonal agents made it possible to predictively interfere with hor­ mone actions. Besides the intellectual challenge of modulating the hormone system, there is an important new aspect associated with recent research on hormones and cancer: new developments have generally led to a reduction in treatment-induced morbidity. As aromataseinhibitors are substituted for adrenalectomy, controlled interference with the hypothalamic-gonadotrophic axis is likely to replace surgical removal of the relevant glands, i. e. , the pituitary gland or the gonads. With the detection of the luteinizing hormone releasing hormone (LH-RH), its structural analysis, and the synthesis of analogs of this decapeptide hormone, a tool became available not only for treatment of sterility or endometriosis but also for switching off gonadal activity in a reversible manner. Evidence has accumulated over the past few years that LH-RH agonists can serve as "medical orchiectomy" in prostate cancer. As a logical consequence, hypogonadotropic gonadal insufficiency induced by LH-RH agonists was investigated in patients with breast cancer. Of equal importance were the attempts to prevent infertility from cytostatic drugs by temporar­ ily suspending gonadal function.

Editors and Affiliations

  • Innere Klinik und Poliklinik Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Essen 1, Federal Republic of Germany

    Klaus Höffken

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation